This article was corrected | View correction
To the Editor: Drs Volkow and McLellan1 recognize that it is by well-crafted, multifaceted public health approaches involving prescribers and the public that prescription opioid–related morbidity and mortality can be curtailed while preserving access to medically indicated opioid therapy. They point to important aspects of assessment and ongoing monitoring in risk management, including the use of urine drug testing. We are concerned that while overall costs of care and potential benefits of routine urine drug testing are being established,2 the coverage determination language of the Centers for Medicare & Medicaid Services and their contracted fiscal intermediaries does not support these contemporary principles of practice. For example, Medicare requires a suspicion of illicit drug use before covering routine preventive toxicology screens.3 This stands in contradiction to the position of Volkow and McLellan.1
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 3
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.